What is MediWound?
Founded in 2001 and headquartered in Israel, MediWound is dedicated to the development, manufacturing, and commercialization of innovative therapeutics. The company leverages its patented proteolytic enzyme technology to address critical unmet needs in the treatment of severe burns, chronic wounds, and other hard-to-heal conditions. This focus positions MediWound within the rapidly evolving biopharmaceutical sector, aiming to provide advanced solutions where traditional methods fall short.
How much funding has MediWound raised?
MediWound has raised a total of $85.7M across 3 funding rounds:
Stock Offering
$70M
Unspecified
$9M
Other Financing Round
$6.7M
Stock Issuance/Offering (2014): $70M, investors not publicly disclosed
Unspecified (2022): $9M led by Biomedical Advanced Research and Development Authority (BARDA
Other Financing Round (2023): $6.7M supported by U.S. Department of Defense
Key Investors in MediWound
Biomedical Advanced Research and Development Authority (BARDA
BARDA is a U.S. government entity focused on enhancing public health security by facilitating the development of innovative medical countermeasures. They partner with innovators to support promising medical technologies from preclinical stages to FDA approval, indicating a focus on advanced healthcare solutions with national security implications.
U.S. Department of Defense
The U.S. Department of Defense is the federal department responsible for national security and the Armed Forces. Their investment in MediWound suggests a strategic interest in advanced medical technologies that can support military personnel and potentially broader public health applications, particularly in trauma and wound care.
What's next for MediWound?
The recent major strategic investment, coupled with the overall enterprise-level funding, signals a strong confidence in MediWound's technology and market potential. This capital infusion is likely to accelerate the company's research and development pipeline, potentially enabling further clinical trials, manufacturing scale-up, and broader commercialization efforts. The strategic nature of the recent financing suggests a focus on expanding market reach and solidifying its position in the competitive wound care landscape.
See full MediWound company page
